Medicenna Therapeutics (NASDAQ:MDNA) Stock Suddenly Gains Momentum On High Volume

January 20, 2022

This morning man investors are possibly going to focus on the clinical stage immuno-oncology firm Medicenna Therapeutics (NASDAQ:MDNA), considering the fact that its stock had moved strongly on Wednesday. Trading Data On Wednesday, MDNA stock moved up 7.70% to $1.54 with more than 94k shares, compared to its average volume of 204K shares. The stock has moved within a range of $1.4700 – 1.5500 after opening trade at $1.47. Medicenna…


Medicenna Therapeutics Corp (NASDAQ:MDNA) Stock Gains Momentum: Now What?

September 28, 2021

Medicenna Therapeutics Corp (NASDAQ:MDNA) has appointed John H. Sampson, MD, PhD, MBA, to its Board of Directors. Fahar Merchant, PhD, President and CEO of Medicenna, is elated to welcome a world renowned clinician-scientist into their fold. He believes his expertise in leading novel clinical trials, interactions with regulators and translational immuno-oncology, will pave the way to develop MDNA11, enhance their MDNA55 program with a partnership, and build on their Superkine…


Medicenna Therapeutics Corp (NASDAQ: MDNA) Reported Loss of $17.3 Million For The Year Ended March 31, 2021

July 28, 2021

Medicenna Therapeutics Corp (NASDAQ: MDNA) is an immuno-oncology company that announced the financial performance for the year ended March 31, 2021, where the company reported a loss of $17.3 million. In addition, the company guided the way for future growth. Besides this, the company also informed about the MDNA11 phase 1/ 2 study initiation on track. Reported loss; see promising future: During the year ended March 31, 2021, the company…